[CAS NO. 1048668-70-7] AZD8329
PRODUCTS SPECIFICATIONS [1048668-70-7]
DESCRIPTION [1048668-70-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 421.53 |
| Molecular Formula | C25H31N3O3 |
| SMILES | O=C(O)C1=CC=C(N2N=CC(C(NC3C(C4)CC5CC4CC3C5)=O)=C2C(C)(C)C)C=C1 |
Summary
AZD8329 is a potent 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with an IC 50 of 9 nM for human 11β-HSD1, displays excellent selectivity versus 11β-HSD2, 17β-HSD1 and 17β-HSD3 [1] .
IC50 & Target
IC50: 9 nM (Human 11β-HSD1) [1]
In Vitro
AZD8329 shows IC 50 s of 0.009, 0.0086, 0.008, 0.024, 0.002 and 6.1 μM for human enzyme, rat enzyme, dog enzyme, cyno enzyme, human adipocyte and mouse enzyme, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01225939 | AstraZeneca |
Type 2 Diabetes Mellitus
|
November 2010 | Phase 1 |
| NCT00935662 | AstraZeneca |
Healthy Men
|
July 2009 | Phase 1 |
| NCT01207089 | AstraZeneca |
Overweight|Healthy|Male
|
September 2010 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 62.5 mg/mL ( 148.27 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3723 mL | 11.8616 mL | 23.7231 mL |
| 5 mM | 0.4745 mL | 2.3723 mL | 4.7446 mL |
| 10 mM | 0.2372 mL | 1.1862 mL | 2.3723 mL |